Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,023Revenue $M147Net Margin (%)-41.2Z-Score4.2
Enterprise Value $M3,666EPS $-0.6Operating Margin %-35.1F-Score2
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-45.2Higher ROA y-yN
Price/Book11.010-y EBITDA Growth Rate %0Quick Ratio6.9Cash flow > EarningsY
Price/Sales26.45-y EBITDA Growth Rate %34.6Current Ratio7.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-7.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-16.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M118ROI % (ttm)-13.6Gross Margin Increase y-yN

Gurus Latest Trades with ISIS

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ISISGeorge Soros 2014-06-30 Sold Out $22.98 - $43.33
($31.44)
$ 34.179%Sold Out0
ISISRon Baron 2014-06-30 Sold Out -0.01%$22.98 - $43.33
($31.44)
$ 34.179%Sold Out0
ISISRon Baron 2014-03-31 Buy 0.01%$38.56 - $59
($48.28)
$ 34.17-29%New holding, 45251 sh.45,251
ISISGeorge Soros 2014-03-31 Buy $38.56 - $59
($48.28)
$ 34.17-29%New holding, 5539 sh.5,539
ISISGeorge Soros 2011-06-30 Sold Out $8.54 - $9.38
($8.92)
$ 34.17283%Sold Out0
ISISGeorge Soros 2011-03-31 Buy $8.57 - $10.35
($9.21)
$ 34.17271%New holding, 22300 sh.22,300
ISISJean-Marie Eveillard 2010-12-31 Sold Out -0.01%$8.05 - $10.51
($9.48)
$ 34.17260%Sold Out0
ISISJean-Marie Eveillard 2010-09-30 Buy 0.01%$7.775 - $10.07
($8.76)
$ 34.17290%New holding, 100000 sh.100,000
ISISGeorge Soros 2010-09-30 Sold Out $7.775 - $10.07
($8.76)
$ 34.17290%Sold Out0
ISISGeorge Soros 2010-06-30 Buy $8.84 - $11.13
($9.93)
$ 34.17244%New holding, 16100 sh.16,100
ISISJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$8.66 - $11.76
($10.31)
$ 34.17231%Sold Out0
ISISJean-Marie Eveillard 2009-12-31 Buy 0.01%$9.94 - $14.16
($11.94)
$ 34.17186%New holding, 50000 sh.50,000
ISISJean-Marie Eveillard 2007-12-31 Sold Out $15.4 - $17.69
($16.7)
$ 34.17105%Sold Out0
ISISJean-Marie Eveillard 2007-09-30 Buy $9.74 - $14.97
($12.1)
$ 34.17182%New holding, 25000 sh.25,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ISIS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ISIS Ron Baron 2014-06-30000Sold Out
ISIS George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ISIS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-08-15Sell5,450$7.01403.28view
CROOKE STANLEY TChairman, President and CEO 2014-08-13Sell17,100$35.45-0.48view
O'NEIL PATRICK R.SVP, Legal and General Counsel 2014-08-12Sell1,500$350.8view
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-08-08Sell7,600$6.87413.54view
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-08-01Sell5,350$6.35455.59view
CROOKE STANLEY TChairman, President and CEO 2014-08-01Sell16,000$30.5315.56view
Monia Brett PSVP, Antisense Drug Discovery 2014-07-31Sell79$31.512view
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-07-25Sell5,250$6.75422.67view
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-07-18Sell13,500$6.66429.73view
ISIS PHARMACEUTICALS INCDirector, 10% Owner 2014-07-11Sell8,050$6.73424.22view

Press Releases about ISIS :

    Quarterly/Annual Reports about ISIS:

    News about ISIS:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
    Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
    Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
    Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
    Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    Guru Stocks at 52-Week Low: The Dun & Bradstreet Corp, FTI Consulting Inc, Terra Nitrogen Company L. Mar 07 2010 
    Guru Stocks at 52-Week Low: Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, SunPower Corp, Feb 21 2010 
    Weekly Guru Bargains Highlights: Weatherford International, MetroPCS Communications, Isis Pharmaceut Feb 13 2010 
    Weekly Guru Bargain Highlights: Sohu.com Inc, Isis Pharmaceuticals Inc, Netease.com Inc, Barclays PL Feb 06 2010 
    Weekly Guru Bargains Highlights: Isis Pharmaceuticals Inc, MetroPCS Communications Inc, American Int Jan 09 2010 

    More From Our Partners
    US Stock Futures Up Ahead Of Economic Data Aug 15 2014 - BENZINGA

    More From Other Websites
    Nasdaq stocks posting largest percentage increases Aug 20 2014
    Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular... Aug 15 2014
    Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular... Aug 15 2014
    ISIS PHARMACEUTICALS INC Financials Aug 12 2014
    Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss Aug 07 2014
    Isis Reports Financial Results and Highlights for Second Quarter 2014 Aug 04 2014
    ISIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 04 2014
    Isis Reports Financial Results and Highlights for Second Quarter 2014 Aug 04 2014
    Q2 2014 Isis Pharmaceuticals Inc Earnings Release - Before Market Open Aug 04 2014
    Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy Aug 01 2014
    Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy Aug 01 2014
    Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call Jul 28 2014
    Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call Jul 28 2014
    Isis Pharma Initiates Phase II Study on ISIS-APO(a) Jul 21 2014
    Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a) Jul 17 2014
    Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a) Jul 17 2014
    Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx Jul 16 2014
    Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx Jul 16 2014
    What happens when free-speech engines like Twitter and Facebook become megaphones for violence? Jul 15 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide